CCA
BEAM icon

Childress Capital Advisors’s Beam Therapeutics BEAM Stock Holding History

Childress Capital Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25
Closed -$2K – 248
2020
Q4 		$2K Buy
+25
New +$1.23K ﹤0.01% 951

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Childress Capital Advisors's BEAM Position: Q1 2021 in Review

Childress Capital Advisors sold out of Beam Therapeutics (BEAM) in Q1 2021, closing a stake of 25 shares — an estimated $2K sold.

Childress Capital Advisors first reported a position in BEAM in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 209 funds tracked by Wall St. Rank hold BEAM as of Q1 2021.

  • Childress Capital Advisors reported no remaining Beam Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 25 Beam Therapeutics shares in Q1 2021, an estimated $2K.
  • Childress Capital Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Beam Therapeutics position peaked at $2K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.